Shopping Cart
- Remove All
- Your shopping cart is currently empty
Anti-4-1BB/CD137/TNFRSF9 Antibody (3F774) is a Rabbit antibody targeting 4-1BB/CD137/TNFRSF9. Anti-4-1BB/CD137/TNFRSF9 Antibody (3F774) can be used in ELISA.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 μL | $199 | 7-10 days |
Description | Anti-4-1BB/CD137/TNFRSF9 Antibody (3F774) is a Rabbit antibody targeting 4-1BB/CD137/TNFRSF9. Anti-4-1BB/CD137/TNFRSF9 Antibody (3F774) can be used in ELISA. |
Alias | tumor necrosis factor receptor superfamily, member 9, Ly63, ILA, CDw137, Cd137, AI325004, AA408498, A930040I11Rik, 4-1BB |
Ig Type | Monoclonal Rabbit IgG |
Clone | 3F774 |
Reactivity | Human |
Application | ELISA |
Recommended Dose | ELISA: 1:5000-1:10000 |
Antibody Type | Monoclonal |
Host Species | Rabbit |
Construction | This antibody was obtained from a rabbit immunized with purified, recombinant Human 4-1BB/CD137 (rh 4-1BB/CD137; TMPY-01743; NP_001552.2; Met1-Gln186). |
Purification | Protein A |
Appearance | Liquid |
Formulation | 0.2 μm filtered solution in PBS |
Research Background | CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+and CD8+T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.Cancer ImmunotherapyCo-stimulatory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy |
Conjucates | Unconjugated |
Immunogen | Recombinant Human 4-1BB/CD137 Protein (TMPY-01743) |
Antigen Species | Human |
Biology Area | Cancer Drug Targets |
Stability & Storage | Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free. |
Transport | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.